FDA adds heart risk reduction to Mounjaro's label for type 2 diabetes
Adults with type 2 diabetes and existing artery disease now have a heart-related reason on the label to use Mounjaro, though the trial did not show it outperformed the comparison drug.
The Food and Drug Administration has approved Mounjaro (tirzepatide) for a second use: lowering the chance of cardiovascular death, non-fatal heart attack or non-fatal stroke in adults with type 2 diabetes who face a high risk of those events [1][2]. Eli Lilly announced the decision on Aug. 28, 2026 [1].
Mounjaro was already cleared to improve blood sugar in adults and children 10 and older with type 2 diabetes [1][2]. The new labeling adds a cardiovascular indication on top of that [1][2].
The evidence comes from SURPASS-CVOT, which Lilly calls the largest and longest tirzepatide trial so far and the first cardiovascular outcomes study to test two incretin medicines against each other instead of against a placebo [1]. It enrolled 13,299 people with type 2 diabetes and established atherosclerotic cardiovascular disease, assigned them one-to-one at 640 sites in 30 countries, and followed them for a median of 210.1 weeks [1]. One group received weekly under-the-skin tirzepatide at 15 mg or the highest dose they could tolerate; the other received weekly dulaglutide (Trulicity) 1.5 mg, a GLP-1 medicine that already carries a cardiovascular risk-reduction indication [1].
For the main measure — the combined rate of cardiovascular death, heart attack or stroke — the hazard ratio was 0.92, with a 95.3% confidence interval of 0.83 to 1.01 [1]. Lilly describes that as an 8% lower rate of those events [1]. The study met its goal of showing tirzepatide was non-inferior to dulaglutide, meaning it was not worse; it did not establish superiority, meaning tirzepatide was not shown to be better [1].
Because there was no placebo group, the trial does not answer how either drug compares with no incretin treatment [1]. Lilly's announcement also did not report all-cause death results.
Side effects in the trial matched what was already known, Lilly said: mostly gastrointestinal, generally mild to moderate, and concentrated in the period when doses are increased [1]. The label carries a boxed warning about thyroid C-cell tumors and lists pancreatitis, low blood sugar when combined with insulin or sulfonylureas, serious allergic reactions, kidney injury from fluid loss, severe stomach problems, worsening diabetic retinopathy, gallbladder disease and aspiration during anesthesia or deep sedation among its warnings [2]. Nausea, diarrhea, reduced appetite, vomiting, constipation, indigestion and stomach pain are the most common side effects [1][2].
"Heart health deserves attention throughout the course of treatment, not just after a serious cardiovascular event," said David A. D'Alessio, M.D., a study co-author and director of the Division of Endocrinology and Metabolism at Duke University School of Medicine [1].
Why it matters for patients
For someone who has both type 2 diabetes and hardening of the arteries, the label now gives a heart-related reason to consider Mounjaro, not only a blood-sugar reason [1][2]. Lilly estimates that up to one in three U.S. adults with type 2 diabetes have cardiovascular disease that has not been detected [1].
The scope is narrow. It applies to adults with type 2 diabetes at high cardiovascular risk [1][2]. It does not extend to people without type 2 diabetes, and it is not a weight-loss indication [1][2].
It also does not settle which drug is the stronger heart medicine. Since superiority was not established, the trial did not show a meaningful difference between tirzepatide and dulaglutide on the main cardiovascular measure [1].
Whether insurers will pay for Mounjaro under the new indication, and on what terms, has not been disclosed. Whether the same cardiovascular benefit would appear in people without type 2 diabetes has not been reported.
What happens next
DailyMed, the National Library of Medicine's label service, shows the Mounjaro prescribing information updated Aug. 27, 2026, with major adverse cardiovascular events listed as an indication [2]. Trial data is already reflected in Mounjaro's product information in the European Union, and Lilly says submissions based on the study are under review in other markets; no decision dates were given [1]. The full SURPASS-CVOT results were published in the New England Journal of Medicine [1].
Sources
Semaglutides.org provides information only, not medical advice. Talk to a licensed provider about your own care before making changes. Some telehealth links are affiliate links and are labeled where they appear.